Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Braz J Microbiol ; 53(2): 935-945, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-35150432

RESUMO

Probiotics have been used for the treatment of chronic metabolic diseases, including type 2 diabetes (T2D). However, the mechanisms of antidiabetic effects are not well understood. The object of this study is to assess the antidiabetic effect of Lactiplantibacillus plantarum Y15 isolated from Chinese traditional dairy products in vivo. Results revealed that L. plantarum Y15 administration improved the biochemical indexes related to diabetes, reduced pro-inflammatory cytokines, L. plantarum Y15 administration reshaped the structure of gut microbiota, decreased the abundance of LPS-producing, and increased short-chain fatty acids (SCFAs)-producing bacteria, which subsequently reduce the levels of lipopolysaccharide (LPS) and pro-inflammatory cytokines. L. plantarum Y15 administration also regulated the expressions of the inflammation and insulin signaling pathway-related genes. These results suggest that L. plantarum Y15 may serve as a potential probiotic for developing food products to ameliorate T2D.


Assuntos
Diabetes Mellitus Tipo 2 , Microbioma Gastrointestinal , Lactobacillus plantarum , Probióticos , Animais , Citocinas/metabolismo , Diabetes Mellitus Tipo 2/tratamento farmacológico , Microbioma Gastrointestinal/fisiologia , Hipoglicemiantes/farmacologia , Insulina/metabolismo , Insulina/farmacologia , Lactobacillus plantarum/metabolismo , Lipopolissacarídeos/farmacologia , Camundongos , NF-kappa B/genética , NF-kappa B/metabolismo , Transdução de Sinais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA